Investment Rating - The report assigns an "Outperform" rating for the company [2][9]. Core Insights - The company is experiencing a potential operational turning point, with increased accounts receivable and inventory due to seasonal factors, but the risk of uncollectible accounts is considered low [5][13]. - The company has a strong grassroots sales channel, with a significant number of sales personnel, and has secured domestic agency rights for major products from Merck and GSK [6][23]. - The HPV vaccine is entering a mature phase, but there is still room for growth in vaccination rates among eligible women and potential expansion into male indications [6][25]. - The company has signed an exclusive distribution agreement for GSK's shingles vaccine, with projected minimum annual procurement amounts indicating confidence in the market potential [6][30][32]. - The company is expanding its product pipeline with self-developed vaccines and plans to acquire a biopharmaceutical company to enter the diabetes and obesity treatment market [6][37]. Summary by Sections Accounts Receivable and Inventory - In Q1 2024, accounts receivable increased by 11% to 30.03 billion yuan, while inventory rose by 40% to 12.61 billion yuan [5][13]. - The accounts receivable turnover days are significantly lower than peers, indicating efficient collection processes [16]. Operational Advantages and Growth Potential - The company has a robust marketing network covering all provinces and a large sales team of 3,990 personnel, which is much higher than industry peers [6][23]. - The company’s revenue for 2023 was 52.9 billion yuan, a 38% increase year-on-year, with agency business revenue growing by 48% [24]. - The company is focusing on a "second curve" of growth through new product launches and acquisitions [24][37]. Shareholder Returns - The company plans to distribute a total of at least 10 yuan per 10 shares in dividends for 2023 and 2024, corresponding to a dividend yield of 3.5% based on the stock price [7][38]. - The company has completed a share buyback worth 300 million yuan [7][38]. Financial Forecast and Valuation - The company is projected to achieve net profits of 9.22 billion, 11.32 billion, and 12.71 billion yuan for 2024-2026, with respective growth rates of 14%, 23%, and 12% [9][40]. - The estimated reasonable valuation range for the company is between 38.50 and 46.20 yuan per share, based on a P/E ratio of 10-12 times [9][40].

北京市金杜（重庆）律师事务所 关于重庆智飞生物制品股份有限公司 2023 年年度股东大会的法律意见书 致：重庆智飞生物制品股份有限公司 北京市金杜（重庆）律师事务所（以下简称本所）接受重庆智飞生物制品股份 有限公司（以下简称"公司"）的委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券 监督管理委员会《上市公司股东大会规则（2022 年修订）》（以下简称"《股东 大会规则》"）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目 的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾地区）现行有效 的法律、行政法规、规章、规范性文件和现行有效的《重庆智飞生物制品股份有限 公司章程》有关规定，指派律师出席了公司于 2024 年 6 月 18 日召开的 2023 年 年度股东大会（以下简称"本次股东大会"），并就本次股东大会相关事项出具本 法律意见书。 为出具本法律意见书，本所律师审查了以下文件，包括但不限于： 1．经公司 2023 年 11 月 16 日召开的 2023 年第一次临时股东大会审议通过 的《重庆智飞生物制品股份有限公司章程 ...

证券代码：300122 证券简称：智飞生物 公告编号：2024-31 2.本次股东大会未涉及变更前次股东大会决议。 一、会议召开和出席情况 1、会议召开情况 载、误导性陈述或重大遗漏。 重要提示 （1） 时间： 1.本次股东大会未出现否决议案的情形； 重庆智飞生物制品股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 现场会议：2024年6月18日（星期二）上午10:00； 网络投票：2024年6月18日。其中，通过深圳证券交易所交易系统进行网络投票 的时间为2024年6月18日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳证券 交易所互联网系统投票的具体时间为：2024年6月18日9:15-15:00； （2） 现场会议地点：重庆市江北区金源路9号重庆君豪大饭店； （3） 会议方式：本次会议以现场投票与网络投票相结合的方式召开； （6） 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股东大会规则》等有关法律、行政法规、部门规 章、规范性文件及《重庆智飞生物制品 ...

Investment Rating - The investment rating for the company is "Buy" with a maintained rating [7] Core Views - The company achieved a revenue of 52.918 billion yuan in 2023, representing a year-on-year growth of 38.30%. The net profit attributable to the parent company was 8.070 billion yuan, up 7.04% year-on-year [1] - The sales of HPV vaccines are showing robust growth, with the nine-valent HPV vaccine issuing 36.55 million doses, a year-on-year increase of 136.16% [2] - The partnership with GSK for the recombinant shingles vaccine is expected to contribute positively to sales starting this year [3] - The company is making significant progress in its self-developed products, with several vaccines entering various stages of clinical trials and approvals [4] Financial Performance Summary - In Q1 2024, the company reported a revenue of 11.396 billion yuan, a year-on-year increase of 2.00%, but a net profit decrease of 28.26% to 1.458 billion yuan [1] - The revenue forecast for 2024-2025 has been adjusted to 61.559 billion yuan and 59.165 billion yuan respectively, with net profit forecasts adjusted to 8.833 billion yuan and 9.386 billion yuan [5] - The company's financial metrics show a projected revenue growth rate of 16.33% for 2024, followed by a decline of 3.89% in 2025 [6]

Group 1: Company Performance and Product Development - The current contribution of agency products to the company's performance is significant, but there is a clear plan for the development of self-owned products over the next 3 to 5 years [1] - The company aims to increase the number of self-owned products significantly within the next 5 years, enhancing their contribution to overall performance [2] - There are currently 31 non-COVID projects under research, with 14 in clinical stages, including various vaccines expected to progress [2] Group 2: Market Opportunities and Strategies - The domestic market for HPV vaccines is substantial, with approximately 320 million women aged 9-45, and a current vaccination rate of about 21%, indicating a large potential for growth [2] - The company plans to enhance public awareness and vaccination rates for cervical cancer prevention through disease education and promotion of HPV vaccines [3] - The company has successfully taken over the promotion of GSK's recombinant shingles vaccine, with positive sales progress reported [3] Group 3: Financial Management and Profit Distribution - As of the end of 2023, the company's accounts receivable reached 27.059 billion yuan, with a healthy proportion (94%) of receivables aged within one year [4] - The company plans to distribute a cash dividend of 8.00 yuan per 10 shares, totaling 1.915 billion yuan, with cumulative dividends expected to exceed 6.839 billion yuan [5] - The company has implemented a share buyback plan, repurchasing 6,210,253 shares, accounting for 0.26% of the total share capital [12] Group 4: Research and Development Focus - The company has 17 projects in clinical trial and registration stages, focusing on self-research and development as a primary strategy [5] - The company is developing a diverse product pipeline, including vaccines for pneumonia and other diseases, with a strong emphasis on innovative research [6] - The acquisition of Chen'an Biotech aims to expand the company's portfolio into metabolic diseases, enhancing its therapeutic capabilities [6] Group 5: Compliance and ESG Initiatives - The company has established a compliance management system based on prevention, monitoring, and punishment, with extensive training conducted for employees [8] - The company has received recognition for its ESG efforts, including awards for charitable contributions and an upgraded ESG rating to "BBB" by MSCI [8] - The company is committed to enhancing its governance structure and environmental management, with significant investments in sustainability initiatives [8]

Investment Rating - The report maintains an "Accumulate" rating for the company [2][8] Core Views - In 2023, the company achieved a revenue of 52.918 billion yuan, representing a year-on-year increase of 38.30%, and a net profit attributable to shareholders of 8.07 billion yuan, up 7.04% year-on-year [3][5] - The company has strengthened its research and marketing advantages, with new international collaborations and the acquisition of Chen'an Biotech, establishing a "prevention + treatment" biopharmaceutical platform [2][8] - The company is expected to maintain steady growth, with projected net profits of 10.509 billion yuan, 11.075 billion yuan, and 11.856 billion yuan for 2024-2026, corresponding to a PE ratio of 8.3, 7.9, and 7.4 times, respectively [2][8] Financial Summary - In 2023, the company reported a net cash flow from operating activities of 8.996 billion yuan, a significant increase of 352.30% year-on-year [3][5] - The company's revenue is projected to grow to 60.285 billion yuan in 2024, with a year-on-year growth rate of 13.9% [4][9] - The gross profit margin is expected to improve from 26.9% in 2023 to 29.9% in 2024 [4][9] Product Development and Market Position - The company has seen strong growth in its vaccine business, with significant increases in the sales of the nine-valent HPV vaccine, which grew by 136.16% year-on-year [6][8] - The company has invested 1.345 billion yuan in R&D in 2023, accounting for 130.81% of its revenue from self-developed products, indicating a strong commitment to innovation [6][8] - The company is actively expanding its global partnerships, including collaborations with Merck and GlaxoSmithKline for the commercialization of vaccines [7][8]

证券研究报告 2024.05.08 公司研报 智飞生物 HPV 疫苗进入稳健成长期，关注带疱疫苗放量 杨一正 分析员 朱言音 分析员 张琎 分析员 医药 医药 医药 SAC 执证编号：S0080523100002 SAC 执证编号：S0080517120001 SAC 执证编号：S0080517040001 yizheng.yang@cicc.com.cn SFC CE Ref：BIH554 SFC CE Ref：BHM689 yanyin.zhu@cicc.com.cn jin.zhang@cicc.com.cn 维 持跑赢行业 业绩回顾 股票代码 股票评级 目标价 2023年业绩基本符合我们预期 300122.SZ → 跑赢行业 人民币52.00 公司公布2023年和1Q24业绩：2023年公司收入529.18亿元，同比增长 38.30%，归母净利润80.70亿元，同比增长7.04%，基本符合我们预期， 股票代码 300122.SZ 公司拟每10股派发现金红利8.0元；1Q24公司收入113.96亿元，同比增 最新收盘价 人民币 36.88 长2.00%，净利润14.58亿元，同比下滑28.26%，主系公 ...

[Table_Page] 年报点评|医药生物 证券研究报告 [智Table_飞Title] 生物（300122.SZ） [公Tab司le_I评nves级t] 买入 当前价格 34.83元 HPV 疫苗持续放量，研发管线迈入收获期 合理价值 65.96元 前次评级 买入 [ 核Tab 心le_S 观umm 点ary] ： 报告日期 2024-04-29 ⚫ 公司发布2023年报及2024年一季报：2023年公司实现收入529.18 [相Tab对le_P市icQ场uote表] 现 亿元（+38.30%，以下均为同比口径）、归母净利润 80.70 亿元 （+7.04%）、扣非归母净利润79.15亿元（+5.40%）；2024Q1公司实 30% 16% 现收入113.96亿元（+2.00%）、归母净利润14.58亿元（-28.26%）、 2% 扣非归母净利润14.55亿元（-28.36%）。 04/23 06/23 08/23 10/23 12/23 02/24 04/24 -12% ⚫ 9 价 HPV 疫苗持续放量，代理 GSK 重组带疱疫苗有望增厚业绩。分 -26% 业务类型看，2023年公司自主产品实现收入10 ...

关于 26 价肺炎球菌结合疫苗获得临床试验批准通知书的公告 证券代码：300122 证券简称：智飞生物 公告编号：2024-29 重庆智飞生物制品股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日收到全资子公司 北京智飞绿竹生物制药有限公司（以下简称"智飞绿竹"）报告，由智飞绿竹自主 研发的 26 价肺炎球菌结合疫苗（以下简称"26 价肺炎结合疫苗"）获得国家药品 监督管理局药物临床试验批准通知书（通知书编号：2024LP01053），同意本品 在 2 月龄及以上人群中开展临床试验。公司将根据临床试验批准通知书的要求， 尽快开展相关临床试验工作。 一、研发项目简介 肺炎球菌是引起婴幼儿和老年人急性呼吸道感染的主要病原菌。肺炎球菌不 仅能引起肺炎，还能导致气管炎、中耳炎、鼻窦炎、脑膜炎、菌血症、肺炎等疾 病。据 WHO 估算，2008 年约有 880 万名 5 岁以下儿童死亡，其中约 47.6 万名 死于肺炎球菌感染，且发展中国家肺炎球菌感染的发病率和死亡率远高于工业化 国家。肺炎球菌性疾病是发病 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1]. Core Insights - The company reported a revenue of 52.92 billion yuan in 2023, representing a year-on-year growth of 38.3%. The net profit attributable to shareholders was 8.07 billion yuan, up 7% year-on-year. However, in Q1 2024, revenue was 11.4 billion yuan, a 2% increase year-on-year, while net profit decreased by 28.3% to 1.46 billion yuan [2][3]. - The decline in net profit in Q1 2024 was primarily due to the impact of returned COVID-19 vaccine sales and changes in product structure affecting profitability. The gross margin for 2023 was 26.9%, down 6.71 percentage points, and the net margin was 15.3%, down 4.45 percentage points [2][3]. - The company has signed an exclusive distribution agreement with GSK for the shingles vaccine, which is expected to generate significant revenue growth from 2024 to 2026, with minimum procurement amounts projected at 3.44 billion yuan, 6.88 billion yuan, and 10.32 billion yuan respectively [2][3]. Summary by Relevant Sections Financial Performance - In 2023, the company achieved a revenue of 52.92 billion yuan, with a growth rate of 38.3%. The net profit attributable to shareholders was 8.07 billion yuan, with a growth rate of 7.04% [3]. - For Q1 2024, the company reported a revenue of 11.4 billion yuan, a 2% increase year-on-year, but net profit fell to 1.46 billion yuan, a decrease of 28.3% [2][3]. Product Structure - The company's revenue from self-produced products was 1.03 billion yuan, down 68.7%, while revenue from agency products was 51.89 billion yuan, up 48.4%. The proportion of the nine-valent HPV vaccine has increased significantly, with sales volume reaching 36.55 million doses, a growth of 136.2% [2][3]. - The company anticipates that the newly added shingles vaccine will provide a new growth point for performance starting next year [2][3]. Earnings Forecast - The expected EPS for 2024-2026 is projected to be 3.78 yuan, 4.44 yuan, and 4.62 yuan respectively. The company maintains a "Buy" rating based on these forecasts [2][3][10].